Opko Health Inc. (NYSE:OPK) was downgraded by stock analysts at TheStreet from a “hold” rating to a “sell” rating in a research report issued on Wednesday.

A number of other equities research analysts have also weighed in on the company. Jefferies Group reiterated a “hold” rating on shares of Opko Health in a research report on Wednesday, August 17th. JPMorgan Chase & Co. set a $14.00 price objective on Opko Health and gave the stock a “buy” rating in a research report on Tuesday, August 9th. Zacks Investment Research upgraded Opko Health from a “sell” rating to a “hold” rating in a research report on Tuesday, October 25th. Finally, Oppenheimer Holdings Inc. reiterated a “hold” rating on shares of Opko Health in a research report on Monday, October 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, four have issued a buy rating and one has given a strong buy rating to the company. Opko Health has an average rating of “Buy” and a consensus price target of $13.20.

Analyst Recommendations for Opko Health (NYSE:OPK)

Shares of Opko Health (NYSE:OPK) opened at 9.38 on Wednesday. Opko Health has a one year low of $7.12 and a one year high of $11.85. The company’s 50-day moving average price is $9.89 and its 200 day moving average price is $9.89. The company has a market cap of $5.16 billion and a P/E ratio of 39.25.

Opko Health (NYSE:OPK) last issued its quarterly earnings data on Monday, November 7th. The company reported ($0.03) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.03). The business earned $298 million during the quarter, compared to the consensus estimate of $322 million. Opko Health’s quarterly revenue was up 108.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.25 earnings per share. On average, equities research analysts anticipate that Opko Health will post ($0.06) earnings per share for the current year.

In related news, CEO Phillip Md Et Al Frost acquired 10,000 shares of the stock in a transaction on Tuesday, August 16th. The stock was acquired at an average price of $10.02 per share, for a total transaction of $100,200.00. Following the completion of the purchase, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $30,750,889.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. ProShare Advisors LLC acquired a new position in Opko Health during the second quarter valued at $100,000. Financial Architects Inc boosted its position in Opko Health by 21.5% in the second quarter. Financial Architects Inc now owns 10,950 shares of the company’s stock valued at $102,000 after buying an additional 1,940 shares in the last quarter. First Citizens Bank & Trust Co. acquired a new position in Opko Health during the second quarter valued at $103,000. Williams Jones & Associates LLC boosted its position in Opko Health by 352.0% in the second quarter. Williams Jones & Associates LLC now owns 11,300 shares of the company’s stock valued at $106,000 after buying an additional 8,800 shares in the last quarter. Finally, IFC Holdings Incorporated FL acquired a new position in Opko Health during the third quarter valued at $113,000.

About Opko Health

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NYSE:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.